Atea Pharmaceuticals, INC Schedule 13D activist filings
Filed when an investor crosses five percent and intends to influence the company — the activist disclosure.
NASDAQ
SCHEDULE 13D/A: Atea Pharmaceuticals Settles Activist Dispute, Appoints New Director and Announces $25 Million Share Repurchase
Atea Pharmaceuticals, Inc. has reached an agreement with the Radoff/JEC Group, leading to a new board appointment and the initiation of a $25 million share repurchase program, while the activist group terminates its formal alliance.
NASDAQ
A group of activist investors, led by Bradley L. Radoff and Michael Torok, has nominated three individuals for election to Atea Pharmaceuticals, Inc.'s board of directors at the upcoming 2025 annual meeting, signaling a potential proxy contest.
NASDAQ
SCHEDULE 13D: Activist Investor Group Takes 5.1% Stake in Atea Pharmaceuticals, Plans Board Challenge
A group of activist investors, including Bradley L. Radoff and Michael Torok, has disclosed a 5.1% beneficial ownership stake in Atea Pharmaceuticals, Inc., expressing dissatisfaction with the current board's ability to oversee a strategic review and announcing plans to nominate a competing slate of director candidates.